百事公司首席执行官近日表示,随着GLP-1类药物的持续创新与成本优化,业界应预见该类代谢疗法将实现更广泛的市场渗透。这一判断折射出食品饮料巨头对新型减肥药物可能改变消费习惯的前瞻性预判。
百事公司首席执行官近日表示,随着GLP-1类药物的持续创新与成本优化,业界应预见该类代谢疗法将实现更广泛的市场渗透。这一判断折射出食品饮料巨头对新型减肥药物可能改变消费习惯的前瞻性预判。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.